Cheil Industries (028260)

Transcription

1 Company Note May 27, 2015 Cheil Industries (028260) 12M rating BUY (Maintain) 12M TP W255,000 from W200,000 Up/downside +36% Stock Data KOSPI (May 26, pt) 2,144 Stock price (May 26, KRW) 188,000 Market cap (USD mn) 23,052 Shares outstanding (mn) Week high/low (KRW) 188,000/113,000 6M avg. daily turnover (USD mn) Free float / Foreign ownership (%) 29.4/2.8 Major shareholders (%) Jae-Yong Lee and 9 others 52.3 KCC Corporation 10.2 Performance 1M 6M 12M Absolute (%) Relative to KOSPI (%p) MF PE trend (X) 12MF PER (LHS) (W' 000) price (RHS) Jun-10 Jun-11 Jun-12 Jun-13 Jun-14 Source: WISEfn consensus Exceeding market expectations again Concerns over overvaluation fading 1) From a long-term perspective, we believe Electronics (SEC) will lift its dividend payout given Cheil Industries (Cheil) s ownership position. Of note, 2016 NP of the Cheil- C&T merged entity is forecast to grow 21.2% assuming SEC s dividend payout ratio rises to 20%. As such, overvaluation concerns should fade as dividend income from SEC ramps up, especially as Cheil should increase its ownership stake as part of a transition to a holding company. 2) Cheil secured brand royalties from C&T via this merger, and the new entity should retain brand royalties from key affiliates, e.g., SEC after a merger with the SEC holdings company. Cheil- C&T entity to be major shareholder of Biologics After the merger, Cheil- C&T is expected to own 19.34% of Life, 4.1% of SEC and 51.4% of Biologics. Currently, Cheil does not book any equity method gains as the Life and SEC stakes have been classified as available-for-sale securities. However, earnings from Biologics will be consolidated as Cheil- C&T will become the largest shareholder. And, we expect Biologics to reach a meaningful earnings level from 2H16 on sales of SB4, the Enbrel biosimilar, in Europe. During an IR session, the group announced early achievement of its original plan (sales of W1.8tn, OPM 40% targeted for 2020) appears possible given the robust bio business growth. NAV per share calculated at W255,000 NAV per share less treasury stock is calculated at W255,000, equivalent to a fair market cap of W42.3tn. As such, we revise up our TP by 27.5% from W200,000 to W255,000. 1) We increased the operating value of the construction business to W6.7tn (including C&T s trading business), 2) we reflected fair value of W12.7tn on securities held by C&T, including a 4.1% stake in SEC and a 17.1% stake in SDS, and 3) we reflected an additional 5.75% stake in Biologics while deducting net debt from C&T. Of note, additional operating value was reflected as C&T has traded at a discount to asset value. To reflect the holding company transition, we discounted future cash flows, including dividend income and brand royalties, by 70% in our DCF valuation. While we reflected EPS dilution during the merger process, we expect to revise our discount rate and TP as the transition gains traction. Taeho Yoon taeho3123@truefriend.com Seoyeon Kim seoyeon.kim@truefriend.com Yr to Sales OP NP EPS % chg EBITDA PE EV/EBITDA PB ROE DY Dec (W bn) (W bn) (W bn) (KRW) (YoY) (W bn) (x) (x) (x) (%) (%) 2013A 3, ,086 1, NM 7.1 NM A 5, ,375 (81.3) F 5, (73.3) F 5, , F 6, , Note: Net profit and EPS are based on figures attributed to controlling interest Analysts who prepared this report are registered as research analysts in Korea but not in any other jurisdiction, including the U.S. PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES & DISCLAIMERS AT THE END OF THIS REPORT.

2 Table 1. Comparison between Cheil Industries and C&T F 2016F 2017F (W bn, 000 shares, X, KRW) Cheil(A) C&T(B) (A)+(B) Cheil(A) C&T(B) (A)+(B) Cheil(A) C&T(B) (A)+(B) Cheil(A) C&T(B) (A)+(B) Sales 5,130 28,446 33,576 5,188 26,986 32,173 5,992 27,579 33,571 6,698 27,948 34,645 Operating profit EBT Net income (adj. dividend income from SEC) controlling NP Shareholders' equity 5,285 13,672 18,958 5,745 15,993 21,738 6,247 18,361 24,608 6,773 20,763 27,537 Market cap 21,505 8,712 30,216 21,505 8,712 30,216 21,505 8,712 30,216 21,505 8,712 30,216 # of shares 135, , , , , , , , , , , ,690 outstanding PER EPS 3,375 1,735 3, ,576 2,401 1,189 1,877 2,928 1,370 2,100 3,301 PBR BPS 39,150 87,522 99,941 42, , ,600 46, , ,728 50, , ,167 Note: Price calculated in merger applied Source: Company data, Korea Investment & Securities Table 2. Deal details (KRW) Existing entity Cheil Industries Merged entity C&T Share exchange ratio 1 : Common shares 189,690 Preferred shares 1,627 % of treasury stock 12.7 Standard price Common shares Cheil Industries 159,294 C&T 55,767 Preferred shares Cheil Industries 99,432 C&T 34,810 Exercise price in appraisal right Cheil Industries 156,493 C&T Common stock 57,234 C&T Preferred stock 34,886 Major schedules Date of board decisions May 26 Announcement in holding a shareholders' meeting July 2 Expected date of shareholders' meeting July 17 Periods available for exercising appraisal right July 17~August 6 Periods offered for creditors to submit objection July 18~August 18 Date of merger September 1 Issuance of new shares September 14 Listing of new shares September 15 Source: Korea Investment & Securities 2

3 Table 3. Changes in major shareholders post-merger (shares, %) Cheil Industries C&T Merged entity # of % of Shareholder shareholding shareholding Shareholder # of shareholding % of shareholding Shareholder # of % of shareholding shareholding Jae-Yong Lee 31,369, Keon-Hee Lee 2,206, Keon-Hee Lee 5,425, KCC 13,750, NPS 20,537, Jae-Yong Lee 31,369, Bu-Jin Lee 10,456, SDI 11,547, Bu-Jin Lee 10,456, Seo-Hyun Lee 10,456, F&M 7,476, Seo-Hyeon Lee 10,456, Keon-Hee Lee 4,653,400 Welfare 3.4 Foundation 231,217 Other special 0.1 relatives 709, Yoo-Jeong 600, Foundation of Lee Culture 123, SDI 9,042, Woon-Hae Cho 100, Shin Kim 26, SEMCO 5,000, SEMCO 5,000, Treasury stock 8,990, F&M 2,617, SDI 5,000, Foundation of 1,144, Culture C&T 1,849, Welfare 80, Foundation Foundation of 1,101, KCC 13,750, Culture Treasury stock 19,033, Treasury stock 24,031, Outstanding shares Note: As of end-march ,000, Outstanding shares 156,217, Outstanding shares Source: DART, Korea Investment & Securities 189,690, Figure 1. group ownership structure post-merger Keon-Hee Lee and relatives 4.8% 2.6% Biologics 51.4% 30.4% Cheil Industries 12.7% 1.4% 19.3% 20.8% Life 5.5% 15.0% SDS 0.04% 17.1% F&M 12.4% 22.6% 4.1% 7.2% Card 0.4% 34.4% SDI0.05% 19.6% SEC 12.1% 1.3% 11.1% Securities 5.5% SEMCO 0.05% 23.7% Note: As of end-december 2014/ Price calculated in merger applied Source: DART, Korea Investment & Securities 3

4 Table 4. Cheil Industries SotP valuation Cheil (A) C&T (B) Merged entity (A)+(B) Assumption (A) Operating value = 6,408 5,690 12,099 (a)+(b)+(c)+(d) (a) Operating value of fashion W bn 2,153 2,153 business EBITDA W bn F EBITDA EV/EBITDA x 14.9 Average of Hansom(manufacturer), Shinsegae International(importer) Operating income W bn F Operating income (b) Operating value of food business W bn 2,783 2,783 EBITDA W bn F EBITDA EV/EBITDA x 16.7 Shinsegae food EV/EBITDA Operating income W bn F Operating income (c) Operating value of construction business W bn 995 5,690 6,685 EBITDA W bn Simple addition to 2015F EBITDA on 2015F OP of C&T EV/EBITDA x % discount over industry average Operating income W bn F Operating income (d) Revised Operating value of leisure business W bn Land of resort is not included Operating value of leisure business W bn 553 EBITDA W bn F EBITDA EV/EBITDA x 7.1 global peer - 40% discount Operating income W bn F Operating income (B) Non-operating value = (e)+(f)+(g) 14,037 13,627 27,664 (e) Real estate W bn 2,365-50% hilly area 2014 appraisal value of Everland s appraisal site - 27% allowed for development Nearby land value (forest, housing sites) - 23% for facility Land value of Lakeside Country Club (f) Securities W bn 4,551 12,730 Close-May 26 - SEC 4.06% 8,145 - Life 19.34% 4,487 - SDS 17.08% 3,747 - Cheil Worldwide 12.64% Engineering 7.81% Fine Chem 5.59% 61 - Securities 0.26% 12 - Heavy Industries 0.13% 6 - imarket Korea 0.47% 5 - Other securities (not listed) Book value as of December 2014 (g) Biologics stake value W bn 7, ,018.2 Subtract net debt from operating value of Bioepis and Biologics - Estimated market cap. of W bn Biologics 15,600 15,600 Biologics: Apply PS of Celltrion and Isu Abxis - % of holding stake % 45.65% 5.75% (C) Premiums on holding firm transition 4,780 4,780 - discount factor 70.0% Apply discount factor considering the future value - value in holding firm transition 15, % of WACC effective in calculating PV of dividend income and brand royalties - dividend income from affiliates 9,525 20% of dividend payout ratio effective - brand royalties income 6, % of sales from SEC, C&T, Life and F&M (D) Net debt 1,120 1,154 2,274 Subtract short-term financial asset value from financial debt (both short and long-term debt incl.) value, as of end-2014 Debt 1,496 3,454 4,950 Cash&CE 373 1,801 2,174 Non-controlling equity (D) Total enterprise value = (A)+(B)+(C)-(D) 42,268 Shares outstanding Share 189,690,043 Total outstanding shares Treasury stock Share 24,033,447 Treasury stocks of 12.7% NAV/share (excl. treasury stock) W 255,000 Subtract treasury stocks Source: Company data, Korea Investment & Securities 4

5 Balance sheet FY-ending Dec. (W bn) 2013A 2014A 2015F 2016F 2017F Current assets 1,753 1,980 2,002 2,313 2,585 Cash & cash equivalent Accounts & other receivables 1, ,002 1,158 1,294 Inventory Non-current assets 6,801 7,531 8,310 9,127 9,915 Investment assets 4,250 4,937 5,450 5,909 6,319 Tangible assets 2,118 2,132 2,392 2,677 2,991 Intangible assets Total assets 8,554 9,511 10,312 11,440 12,500 Current liabilities 1,841 1,266 1,103 1,313 1,589 Accounts & other payables ST debt & bond Current portion of LT debt Non-current liabilities 2,764 2,961 3,464 3,880 4,138 Debentures 798 1,297 1,609 1,805 1,927 LT debt & financial liabilities Total liabilities 4,605 4,226 4,567 5,193 5,727 Controlling interest 3,946 5,283 5,744 6,246 6,773 Capital stock Capital surplus Other Reserves (693) (693) (693) (693) (693) Retained earnings 2,038 2,482 2,597 2,754 2,936 Minority interest Shareholders' equity 3,949 5,285 5,745 6,247 6,773 Income statement FY-ending Dec. (W bn) 2013A 2014A 2015F 2016F 2017F Sales 3,226 5,130 5,188 5,992 6,698 COGS 2,642 3,497 3,625 4,190 4,721 Gross profit 584 1,633 1,563 1,802 1,976 SG&A expense 473 1,419 1,373 1,554 1,695 Operating profit Financial income Interest income Financial expense Interest expense Other non-operating profit (53) (11) (18) (22) (23) Gains (Losses) in associates, subsidiaries and JV (70) (37) Earnings before tax Income taxes Net profit Net profit of controlling interest Other comprehensive profit Total comprehensive profit Total comprehensive profit of controlling interest EBITDA Cash flow FY-ending Dec. (W bn) 2013A 2014A 2015F 2016F 2017F C/F from operating Net profit Depreciation Amortization Net incr. in W/C (48) (118) (11) Others 139 (338) C/F from investing (1,248) 54 (603) (672) (674) CAPEX (163) (186) (432) (487) (547) Decr. in fixed assets Incr. in investment (35) (301) (168) (114) (64) Net incr. in intangible assets (3) (16) (3) (43) (38) Others (1,050) 552 (3) (31) (28) C/F from financing 1,131 (46) Incr. in equity Incr. in debts 1,327 (568) Dividends Others (196) (3) (7) (3) (4) C/F from others (1) Increase in cash Key financial data FY-ending Dec. 2013A 2014A 2015F 2016F 2017F per share data (KRW) EPS 18,086 3, ,189 1,370 BPS 37, ,690 51,409 55,305 DPS Growth (%) Sales growth OP growth (11.3) NP growth (67.9) (73.3) EPS growth 1,408.5 (81.3) (73.3) EBITDA growth Profitability (%) OP margin NP margin EBITDA margin ROA ROE Dividend yield Dividend payout ratio Stability Net debt (W bn) 2,171 1,385 1,713 1,931 2,053 Debt/equity ratio (%) Valuation (X) PE NM PB NM EV/EBITDA Note: Based on K-IFRS (consolidated) 5

6 Changes to recommendation and price target Company (Code) Date Recommendation Price target Cheil Indus. (028260) BUY W107, BUY W200, BUY W255, , , , , ,000 50,000 0 May-13 Sep-13 Jan-14 May-14 Sep-14 Jan-15 May-15 6

7 Guide to Korea Investment & Securities Co., Ltd. stock ratings based on 12-month forward share price performance relative to the market index BUY: Expected to outperform the market index by 15%p or more Hold: Expected to underperform or outperform the market index by less than 15%p Underweight: Expected to underperform the market index by 15%p or more Korea Investment & Securities does not offer target prices for stocks with Hold or Underweight ratings. Guide to Korea Investment & Securities Co., Ltd. sector ratings for the next 12 months Overweight: Recommend increasing the sector s weighting in the portfolio compared to its respective weighting in the Kospi (Kosdaq) based on market capitalization. Neutral: Recommend maintaining the sector s weighting in the portfolio in line with its respective weighting in the Kospi (Kosdaq) based on market capitalization. Underweight: Recommend reducing the sector s weighting in the portfolio compared to its respective weighting in the Kospi (Kosdaq) based on market capitalization. Analyst Certification I/We, as the research analyst/analysts who prepared this report, do hereby certify that the views expressed in this research report accurately reflect my/our personal views about the subject securities and issuers discussed in this report. I/We do hereby also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report. Important compliance notice As of the end of the month immediately preceding the date of publication of the research report or the public appearance (or the end of the second most recent month if the publication date is less than 10 calendar days after the end of the most recent month), Korea Investment & Securities Co., Ltd., or its affiliates does not own 1% or more of any class of common equity securities of Cheil Indus.. There is no actual, material conflict of interest of the research analyst or Korea Investment & Securities Co., Ltd., or its affiliates known at the time of publication of the research report or at the time of the public appearance. Korea Investment & Securities Co., Ltd., or its affiliates has not managed or co-managed a public offering of securities for Cheil Indus. in the past 12 months; Korea Investment & Securities Co., Ltd., or its affiliates has not received compensation for investment banking services from Cheil Indus. in the past 12 months; Korea Investment & Securities Co., Ltd., or its affiliates does not expect to receive or intend to seek compensation for investment banking services from Cheil Indus. in the next 3 months. Korea Investment & Securities Co., Ltd., or its affiliates was not making a market in Cheil Indus. s securities at the time that the research report was published. Korea Investment & Securities Co., Ltd. does not own over 1% of Cheil Indus. shares as of May 27, Korea Investment & Securities Co., Ltd. has not provided this report to various third parties. Neither the analyst/analysts who prepared this report nor their associates own any shares of the company/companies covered in this report as of May 27, Korea Investment & Securities Co., Ltd. has issued ELW with underlying stocks of Cheil Indus. and is the liquidity provider. Prepared by: Taeho Yoon 7

8 Global Disclaimer General This research report and marketing materials for Korean securities are originally prepared and issued by the Research Center of Korea Investment & Securities Co., Ltd., an organization licensed with the Financial Supervisory Service of South Korea. The analyst(s) who participated in preparing and issuing this research report and marketing materials is/are licensed and regulated by the Korea Financial Investment Association in Korea only. This report and marketing materials are copyrighted and may not be copied, redistributed, forwarded or altered in any way without the consent of Korea Investment & Securities Co., Ltd. This research report and marketing materials are for information purposes only. They are not and should not be construed as an offer or solicitation of an offer to purchase or sell any securities or other financial instruments or to participate in any trading strategy. This research report and marketing materials do not provide individually tailored investment advice. This research report and marketing materials do not take into account individual investor circumstances, objectives or needs, and are not intended as recommendations of particular securities, financial instruments or strategies to any particular investor. The securities and other financial instruments discussed in this research report and marketing materials may not be suitable for all investors. The recipient of this research report and marketing materials must make their own independent decisions regarding any securities or financial instruments mentioned herein and investors should seek the advice of a financial adviser. Korea Investment & Securities Co., Ltd. does not undertake that investors will obtain any profits, nor will it share with investors any investment profits. Korea Investment & Securities Co., Ltd., its affiliates, or their affiliates and directors, officers, employees or agents of each of them disclaim any and all responsibility or liability whatsoever for any loss (director consequential) or damage arising out of the use of all or any part of this report or its contents or otherwise arising in connection therewith. Information and opinions contained herein are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or Korea Investment & Securities Co., Ltd. The final investment decision is based on the client s judgment, and this research report and marketing materials cannot be used as evidence in any legal dispute related to investment decisions. Country-specific disclaimer United States: This report is distributed in the U.S. by Korea Investment & Securities America, Inc., a member of FINRA/SIPC, and is only intended for major U.S. institutional investors as defined in Rule 15a-6(a)(2) under the U.S. Securities Exchange Act of All U.S. persons that receive this document by their acceptance thereof represent and warrant that they are a major U.S. institutional investor and have not received this report under any express or implied understanding that they will direct commission income to Korea Investment & Securities, Co., Ltd. or its affiliates. Pursuant to Rule 15a-6(a)(3), any U.S. recipient of this document wishing to effect a transaction in any securities discussed herein should contact and place orders with Korea Investment & Securities America, Inc., which accepts responsibility for the contents of this report in the U.S. The securities described in this report may not have been registered under the U.S. Securities Act of 1933, as amended, and, in such case, may not be offered or sold in the U.S. or to U.S. person absent registration or an applicable exemption from the registration requirement. United Kingdom: This report is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000 of the United Kingdom ("FSMA"). To the extent that this report does constitute such an invitation or inducement, it is directed only at (i) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) of the United Kingdom (the "Financial Promotion Order"); (ii) persons who fall within Articles 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order; and (iii) any other persons to whom this report can, for the purposes of section 21 of FSMA, otherwise lawfully be made (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons must not act or rely on this report. Hong Kong: This research report and marketing materials may be distributed in Hong Kong to institutional clients by Korea Investment & Securities Asia Limited (KISA), a Hong Kong representative subsidiary of Korea Investment & Securities Co., Ltd., and may not otherwise be distributed to any other party. KISA provides equity sales service to institutional clients in Hong Kong for Korean securities under its sole discretion, and is thus solely responsible for provision of the aforementioned equity selling activities in Hong Kong. All requests by and correspondence with Hong Kong investors involving securities discussed in this report and marketing materials must be effected through KISA, which is registered with The Securities & Futures Commission (SFC) of Hong Kong. Korea Investment & Securities Co., Ltd. is not a registered financial institution under Hong Kong s SFC. Singapore: This report is provided pursuant to the financial advisory licensing exemption under Regulation 27(1)(e) of the Financial Advisers Regulation of Singapore and accordingly may only be provided to persons in Singapore who are "institutional investors" as defined in Section 4A of the Securities and Futures Act, Chapter 289 of Singapore. This report is intended only for the person to whom Korea Investment & Securities Co., Ltd. has provided this report and such person may not send, forward or transmit in any way this report or any copy of this report to any other person. Please contact Korea Investment & Securities Singapore Pte Ltd in respect of any matters arising from, or in connection with, the analysis or report (Contact Number: ). Copyright c 2015 Korea Investment & Securities Co., Ltd. All rights reserved. No part of this report may be reproduced or distributed in any manner without permission of Korea Investment & Securities Co., Ltd. 8